A Rapid and Sensitive UPLC-MS/MS Method for Quantifying Capmatinib in Human Liver Microsomes: Evaluation of Metabolic Stability by In Silico and In Vitro Analysis

Capmatinib (CMB) is an orally bioavailable mesenchymal–epithelial transition (MET) inhibitor approved by the US-FDA to treat metastatic non-small cell lung cancer (NSCLC) patients, with MET exon 14 skipping mutation. The current study aimed to establish a specific, rapid, and sensitive ultra-perform...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Mohamed W. Attwa, Ali S. Abdelhameed, Aishah M. Alsibaee, Adnan A. Kadi
Format:	Artigo
Jezik:	Inglês
Izdano:	MDPI AG 2023-04-01
Serija:	Separations
Teme:	capmatinib in vitro half-life metabolic stability intrinsic clearance UPLC-MS/MS P450 model
Online dostop:	https://www.mdpi.com/2297-8739/10/4/247
Oznake:	Označite Brez oznak, prvi označite!